Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

Intraoperative Diaphragmatic Neuromodulation

Phase: N/A Priority: Normal
NCT ID: NCT06518707 Org: User:
Start: 06/01/24 End: 02/01/25 Due: 02/01/26

Electroencephalogram Predicts Post-operative Delirium

Phase: N/A Priority: Normal
NCT ID: NCT06894238 Org: User:
Start: 03/01/25 End: 05/01/26 Due: 05/01/27

Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Phase: N/A Priority: Normal
NCT ID: NCT04070040 Org: User:
Start: 02/13/20 End: 12/31/24 Due: 12/31/25

Retrospective Study of Germ Cell Tumors of the Central Nervous System

Phase: N/A Priority: Normal
NCT ID: NCT05836701 Org: User:
Start: 06/01/23 End: 12/31/24 Due: 12/31/25

Glioblastoma Response Prediction to Apatinib

Phase: N/A Priority: Normal
NCT ID: NCT04814329 Org: User:
Start: 04/22/21 End: 06/30/23 Due: 06/30/24

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

Phase: N/A Priority: Normal
NCT ID: NCT04952571 Org: User:
Start: 06/27/21 End: 12/31/22 Due: 12/31/23

Post-neurosurgical Respiratory Muscle Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT05951114 Org: User:
Start: 07/01/23 End: 03/01/25 Due: 03/01/26

A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

Phase: N/A Priority: Normal
NCT ID: NCT02330991 Org: User:
Start: 01/31/15 End: 09/30/20 Due: 09/30/21

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT02844062 Org: User:
Start: 07/31/16 End: 07/31/19 Due: 07/31/20

Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT04659421 Org: User:
Start: 11/03/20 End: 07/20/23 Due: 07/20/24

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT02937844 Org: User:
Start: 07/31/16 End: 07/31/19 Due: 07/31/20

Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT04267978 Org: User:
Start: 02/13/20 End: 12/31/25 Due: 12/31/26

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Phase: N/A Priority: Normal
NCT ID: NCT04501705 Org: User:
Start: 08/18/20 End: 08/31/25 Due: 08/31/26

Mechanical Ventilation on Hippocampus

Phase: N/A Priority: Normal
NCT ID: NCT06480162 Org: User:
Start: 05/08/24 End: 06/01/25 Due: 06/01/26

Modified CV Regimen in Optic Pathway Glioma

Phase: N/A Priority: Normal
NCT ID: NCT05278715 Org: User:
Start: 04/13/22 End: 12/31/25 Due: 12/31/26

M-I/E for Preventing VAP in Post-neurosurgical Patients

Phase: N/A Priority: Normal
NCT ID: NCT06511986 Org: User:
Start: 03/04/24 End: 03/15/25 Due: 03/15/26

Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

Phase: N/A Priority: Normal
NCT ID: NCT04501718 Org: User:
Start: 10/28/20 End: 08/31/25 Due: 08/31/26